Ann: Paradigm Receives $7.36m R&D Tax Incentive Refund, page-28

LOL that's a great claim............so what you're suggesting then is Bene are now going to breach their exclusivity contract in favour of dealing with some underworld and unregistered Chinese entity?

If you had even the most basic understanding of Chinese pharma market you'd quickly appreciated it one of their more advances market segments and has similar reimbursements hence why all the major BP having a presence. In fact Beverley noted the potential Chinese TAM (including likely discounted pricing) could be 1.5x that of the US.

So whilst they're still a developing country and have plenty of red tape (per most judications) this is not PAR just pissing in the wind.